Biomira is based out of Edmonton Alberta Can. Oncothyreon Inc. researches and develops products to treat cancer; focused on core competency in immunotherapeutics. Its lead cancer vaccine candidate under clinical development is a synthetic Mucin 1 peptide vaccine, BLP25 liposome vaccine (L-BLP25). The firm has no submitted 13F filings and does not appear to be an investment advisor.
Contact Info
Contact information is taken directly from publicly disclosed SEC filings.
BIOMIRA INC2011-94TH STREET
EDMONTON ALBERTA CAN A0 19899-1709
Business Phone: 7804902812
SEC SIC CODE:
2836-BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
2836-BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Recent SEC Filings
Filing | Date |
---|